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Abstract 
Brain tumours are the largest group of solid tumours in children and 
accounts for most cancer-related deaths. Astrocytoma is the largest 
group, representing almost half of the brain tumours, where high-grade 
glioma is one of the most devastating forms with very poor prognosis 
due to lack of efficient treatments. A better understanding of the 
disease and new treatment options are urgently needed.  
 
In paper I, we assessed the possibility of culturing glioma stem cells 
(GSC) from primary paediatric high-grade brain tumours, adherently, 
in serum-free neural stem cell media. Cells maintained proliferative 
capacity long-term, displayed neural stem cell markers and responded 
to differentiation cues. Moreover, cell lines initiated tumour growth 
when orthotopically transplanted into NOG mice.  
 
In paper II, survival of GSC-transplanted NOG mice was monitored, 
and the histological and molecular features of the developed xenograft 
tumours were studied. The survival of mice correlated with the survival 
of the patients. Moreover, the xenograft tumours showed the same 
growth pattern as the patient tumours with similar genetic and 
epigenetic alterations as the originating tumour and GSC line.  
 
In paper III, we explored zebrafish as an animal model to study 
paediatric high-grade gliomas. The tumour-initiating potential and 
invasive properties were studied. The take-rate of transplanted GSC in 
the fish was high, and the cells invaded the surrounding brain tissue of 
the fish after only a few days.  
 
In this thesis, three pre-clinical models were established which can be 
used to generate new knowledge and explore new treatment options 
for paediatric brain tumours.  
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 Sammanfattning på svenska 
 
Hjärntumörer är efter leukemi den vanligaste cancerformen som 
drabbar små barn. Det finns många typer av hjärntumörer och 
prognosen för en del är god, men ändå står sjukdomen för den största 
andelen av cancerrelaterade dödsfall hos barn. Överlevnad är beroende 
av tumörtyp där höggradiga gliom, såsom glioblastom, är en av de 
diagnoser som uppvisar sämst prognos. Idag finns ingen effektiv 
behandling, och behovet av nya behandlingsmetoder är stort.  
 
I denna avhandling utvecklades nya pre-kliniska modeller. 
I den första studien etablerades ett cellodlingssystem med primära 
cellkulturer från höggradiga gliom. Tumörceller odlades i serumfritt 
neuralt stamcellsmedium som adherenta celler. Cellerna uppvisade 
neurala stamcellsegenskaper i form av asymmetrisk celldelning, 
stamcellsmarkörer, och potential att bilda hjärnans mogna celltyper 
(astrocyter, oligodendrocyter och neuroner) samt att bilda tumörer i 
djurmodeller. 
 
I den andra studien följdes tumörutveckling av transplanterade primära 
cellkulturer i immunsupprimerade möss. Överlevnaden av mössen 
korrelerade till överlevnad av patienterna. Xenotransplantaten 
uppvisade tydliga histologiska och molekylära kännetecken för 
glioblastom, samt stora molekylära likheter med det ursprungliga 
tumörmaterialet och cellkulturen.   
 
I den tredje studien undersöktes möjligheten att använda zebrafisk som 
djurmodell för höggradiga hjärntumörer från barn. De primära 
cellkulturerna injicerades i hjärnan hos zebrafiskyngel och invasionen 
av cellerna i hjärnvävnaden följdes.  
 
Sammantaget presenteras tre pre-kliniska, pålitliga och robusta 
cellbaserade modeller. Dessa modeller kan användas för att generera 
kunskap kring glioblastom och bidra till utveckling av nya 
behandlingsmetoder. 
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Introduction 
The word cancer comes from the Greek physician Hippocrates (460‐375 
BC) who described a disease that he named karkinos because its growth 
pattern reminded him of a crab or cray fish. Today we use the term cancer, 
which is the Latin word for karkinos [1]. The disease was  mentioned in 
old writings as early as approximately 3000 BC in the “Edwin Smith 
Papyrus” [2].  
 
In our body, all cells follow specific rules due to body architecture and life 
cycles. If cells leave their predetermined life and start a journey on their 
own, cancer begins. On its way, cells acquire capabilities that are necessary 
to become tumourigenic. Hanahan and Weinberg first proposed six so-
called hallmarks of cancer; sustaining proliferative signals, evading 
growth suppressors, activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis and resisting cell death [3]. 
With the fast and progressive research in the cancer field, an updated 
version of additional hallmarks was presented including; genome 
instability and mutation, deregulating cellular energetics, avoiding 
immune destruction and tumour promoting inflammation [4]. 
Childhood cancer 
Childhood cancer is rare. According to a report from the Swedish 
Childhood Cancer registry, 16.0 per 100 000 children <15 years of age are 
diagnosed with a primary cancer disease each year in Sweden [5]. Under 
the age of ten, the most common diagnoses are leukaemias, representing 
30% of cases, and central nervous system (CNS) tumours, 28% of cases.  
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The 5-year survival for all types of cancer diseases have increased greatly. 
Most improvements have been for acute lymphocytic leukaemia (ALL) 
where the disease was fatal in the 1970s, but show a 5-year survival of 
almost 90% today [5]. Even though survival rates differ considerably 
between cancer types, the increased survival for specific groups encourage 
and inspire more research for all types of tumours to gain knowledge for 
improved treatment options in the future.  
Childhood brain tumours 
Within solid tumours, CNS tumours are the most common type and 
account for the highest number of cancer-related deaths in children <15 
years of age [5, 6]. The incidence is slightly higher in boys (sex distribution 
ratio males/females = 1.10). There is no typical age peak for CNS tumours 
in total, but some tumour types show specific age distributions [5].  
 
There are many different types of childhood brain tumours and this 
paragraph will describe the most prevalent ones. Gliomas are the most 
common type of brain tumours. They originate from neuroepithelial tissue, 
the supporting tissue of the brain [7, 8]. The prognosis is highly dependent 
on the grade of the glioma. Within gliomas, astrocytomas are the largest 
group accounting for approximately 45% of all brain tumours. 
Astrocytoma is subdivided into four grades; low grade I and II (~31% of 
all brain tumours) and high grade III and IV (~6% of all brain tumours), 
where the 5-year survival rates differ largely between 90% and 30%). 
Other types of gliomas in children are ependymomas, originating from 
ependymal cells that line the ventricles (10.5%); oligodendrogliomas, 
originating from oligodendrocytes (2.5%) and brainstem gliomas 
originating from any neuroepithelial cell located in the brainstem (2.6%) 
[7].   
 
The second largest group of brain tumours is embryonal tumours (18.8%). 
The most common type is medulloblastoma, originating from cells in the 
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cerebellum, representing 14.8% of all brain tumours. Atypical 
teratoid/rhabdoid tumour (ATRT) is a less common type of embryonal 
tumour (0.3%) [7]. The diagnosis primitive neuroectodermal tumour 
(PNET) was removed from the last world health organisation (WHO) 
classification as it was shown that these tumours represent other 
established diagnoses [8, 9]. 
Paediatric high-grade glioma 
Glioblastoma multiforme (GBM) is a grade IV astrocytoma and one of the 
most devastating forms of brain tumours. Unlike adult GBM, which is the 
most frequent malignant brain tumour, paediatric GBM is rare with an 
incidence of only 2.7% [10], though both share the same poor 2-year 
survival of only 15-30% and 20-32% respectively [7, 10-13]. Other high-
grade gliomas (HGG) are anaplastic astrocytoma and diffuse infiltrative 
pontine glioma (DIPG) [8].  
 
�e advancements made in molecular profiling of HGG during the last 
decade have unravelled features not detected by histological analysis. With 
the help of genetic and epigenetic features, the paediatric HGG tumours 
can be divided into six groups; K27, G34, IDH (isocitrate dehydrogenase), 
RTK (receptor tyrosine kinase) I, Mesenchymal and PXA (pleomorphic 
xanthoastrocytoma)-like tumours [14]. �e groups are based on DNA 
methylation data, age of onset, tumour location, gene expression, 
oncogenic drivers, and survival time. �e molecular signature is a 
prognostic factor, where K27 tumours show shorter survival time [14-16].  
 
Genetic aberrations and mutations are less common in paediatric HGG 
than in adult brain tumours. The most common copy number alterations 
(CNA) are amplifications including the genes platelet-derived growth 
factor receptor alpha polypeptide (PDGFRA), KIT proto-oncogene 
receptor tyrosine kinase (KIT), kinase insert domain receptor (KDR), 
MYCN proto-oncogene, bHLH transcription factor (MYCN) and 
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epidermal growth factor receptor (EGFR). Deletions most commonly 
occur in cyclin dependent kinase inhibitor 2A (CDKN2A), phosphatase 
and tensin homolog (PTEN) and RB transcriptional corepressor 1 (RB1). 
Somatic mutations are frequently observed in the genes H3 histone family 
member 3A (H3F3A), tumour protein p53 (TP53), ATRX chromatin 
remodeller (ATRX), activin A receptor type 1 (ACVR1) and histone cluster 
1 H3 family member b (HIST1H3B) [17].    
 
Survival from GBM in children is poor and treatment strategies that 
prolong survival in adult GBM show no effect in children [18]. �e 
understanding that adult and paediatric GBM are molecularly very 
different, despite sharing the same name, has led to new ideas and altered 
treatment strategies [19].  
 
In a phase 2 clinical trial, treatment of paediatric HGG patients with 
additional adjuvant treatment (temozolomide (TMZ) and lomustine) after 
standard care (radiation and TMZ) showed an increased survival time 
compared to patients treated with standard care only [20]. In a more recent 
study, the varying response to chemotherapies for the whole group of 
paediatric HGG emphasised the need and importance to direct treatment 
within this group [21]. Molecular profiling, in addition to current diagnostic 
methods, can facilitate this work. The gain of new information regarding 
molecular status of tumours should be considered as additional input for 
pathologists evaluating tumour samples to enable accurate diagnosis. 
During the last years, methylation-based algorithms to classify brain 
tumours have been published, which identify diagnostic entities and 
subgroups [9, 22-24]. The molecular profile of tumours not only helps in 
diagnosing tumours, but also provides additional prognostic information 
and enables targeted treatment designs.  
 
Valproic acid (VPA), an epigenetic drug, has been used as continued 
treatment after complete resection, radiation and intensive chemotherapy 
[25]. In addition, the identification of deregulated components of the 
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epigenetic machinery has led to the discovery of new druggable candidates 
[26]. Enhancer of zeste homolog 2 (EZH2) [27], DNA methyl transferase 
(DNMT) I [28], histone deacetylase (HDAC) [29] and bromodomain and 
extra-terminal motif (BET) [30-32] are some of the potential candidates 
that can move the field forward.     
Epigenetics 
The term Epigenetics, coined by Conrad H. Waddington in 1942, comes 
from the Greek word ‘epi’ referring to over, above, around and ‘genetic’ 
referring to the science of heredity [33]. All cells in our body carry the 
same genetic code, but still exhibit different phenotypes. This is possible 
due to epigenetics. The definition made by Michael K. Skinner “molecular 
factors and processes around DNA that are mitotically stable and regulate 
genome activity independent of DNA sequence” in 2010 summarises the 
concept well [34]. Epigenetics alter the transcription and translation of 
genes in the cell. Upon differentiation, the cell is “locked” into a certain 
path by epigenetic mechanisms and destined to become a specific cell type.  
Epigenetic machinery 
Epigenetics works through three mechanisms; DNA methylation, histone 
modifications and non-coding RNA (Figure 1) [35].  
 
Figure 1: The epigenetic machinery.  
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DNA methylation  
DNA methylation was first described by Holliday and Pugh in the 1970s, 
and was demonstrated to be involved in gene regulation in the beginning 
of the 1980s [36, 37]. Methylation has since then been shown to play an 
important role in biological processes such as development, ageing, 
genomic imprinting and X-chromosome inactivation [38].  
 
The DNA strand contains four nucleotides; guanine (G), cytosine (C), 
adenine (A) and thymine (T) [39]. Methylation most often occurs on the 
5’ carbon residue of cytosine coupled to a guanine and are referred to as 
CpG sites. Throughout the genome, these sites are heavily methylated [40]. 
The methylation process is carried out by DNMT transferring a methyl 
group from S-adenosyl methionine. DNMT1 is involved in sustaining 
methylation after mitosis, and DNMT3a and b are responsible for de novo 
methylation of DNA.  
 
Regions on the DNA strand that contain a high number of cytosines 
followed by guanines are called CpG islands (CGI). These are enriched in 
promoter regions and enhancer regions upstream of genes. CGI are 
predominantly unmethylated [41].  
 
Epigenetic modifications are reversible. Methyl groups can be removed 
from cytosines through passive or active processes. A decrease in DNMT1 
results in a reduction of methylated cytosines in a passive way via mitosis. 
The active process can occur in at least three different multiple step ways, 
involving hydroxylation of 5-methylcytosine (5mC) by the ten-eleven 
translocation (TET) family enzymes or deamination and finally 
replacement of the resulting cytosine intermediates by base excision repair 
(BER) pathways to naked cytosines [42].   
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Histone modifications  
DNA is wrapped around nucleosomes, which are octamer protein 
complexes consisting of duplicates of the histone proteins H2A, H2B, H3 
and H4. Each histone has a residue that can be modified by different 
epigenetic marks (chemical groups), for example methylation, acetylation, 
ubiquitination and phosphorylation.  
 
The modifications are processed by epigenetic writers; enzymes such as 
histone methyltransferase (HMT) and histone acetyl transferase (HAT), 
which add an epigenetic mark, epigenetic erasers; enzymes which remove 
the mark such as histone deacetylase (HDAC) and lysine demethylase 
(KDM) and executed by epigenetic readers; chromodomain-, tudor 
domain- and bromodomain proteins which help interpret the 
modifications. Together these three types of proteins regulate the DNA in 
terms of active/repressed transcription, DNA repair and DNA replication 
[43, 44].  
 
Different modifications constitute specific histone codes; acetylation of 
lysine is for example associated with gene activation. Methylation of 
lysine, on the other hand, has different effects depending on the residue 
that is methylated. Methylated K4 at histone 4 is associated with active 
transcription, while methylated K27 and K9 at histone 3 and K20 at histone 
4 are associated with transcriptional repression. Together these histone 
modifications form a flexible, but very precise DNA packaging [45].   
Non-coding RNA 
Non-coding RNA is RNA that is not translated into protein. There are short 
non-coding RNA, such as microRNA, short interfering RNA (siRNA) and 
piwi interacting RNA (piRNA), and long non-coding RNA. Both groups 
are involved in silencing gene expression by post-transcriptional 
modification [46]. 
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Epigenetic alterations in cancer  
Initiation and progression of cancer are associated with epigenetic 
alterations of the genome. In cancer, the DNA becomes globally 
hypomethylated, mostly due to loss of methylated Cs in repetitive regions 
and demethylation of coding regions and introns [47, 48].  
 
Three proposed events, explaining the unstable signature of cancerous 
cells due to hypomethylation, are induction of oncogene activation, 
generation of chromosomal instability via demethylation of repetitive 
elements, and loss of imprinting [47]. In addition, hypermethylation of 
CGI close to promotor regions of tumour suppressor genes is also common 
in tumour cells [48].  
 
Specific histone modifications play a crucial role in affecting chromatin 
structure and gene transcription. These alterations are commonly 
associated with DNA hypermethylation of tumour suppressor genes [49].  
The plasticity of CSC and their epigenetic marks in the brain is an 
important issue. Previous studies on leukaemia show that terminal 
differentiation of tumour cells may be used to stop tumour growth [50]. 
Even though early data suggested that differentiation-based therapy was 
feasible also for GBM [51], Carén et al later showed that differentiation of 
glioma stem cells (GSCs) does not lead to terminal cell cycle exit [52]. 
GSC responded rapidly, within days, to astrocyte differentiation cues using 
bone morphogenetic protein (BMP) 4 with changed morphology, 
expression of astrocyte markers and stopped proliferation, but this was 
only temporary. Re-exposure to growth factors to both short- and long-
term differentiated cells reactivated proliferation and entrance into the cell 
cycle. As DNA methylation changes does not occur as rapid in GSCs as in 
other more short-lived cells such as leukocytes, the epigenetic machinery 
of the more long-lived cells of the brain needs to be considered in future 
studies.   
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Epigenetic alterations in paediatric high-grade gliomas  
Genes coding for histone proteins are highly conserved and stable. 
However, somatic mutations do occur in these genes and are associated 
with cancer. The genes H3F3A and HIST1H3B/C encode for proteins on 
histone 3 and mutations are associated with amino acids substitutions on 
the histone residues [53-55]. The mutations are frequent in paediatric HGG 
and referred to as H3K27M and H3G34R/V [55, 56]. Mutations are 
location-dependent; H3K27M is found in the midline of the brain and 
H3G34R/V is found exclusively in the hemispheres [57]. H3K27M leads 
to global hypomethylation when the amino acid lysine is replaced by a 
methionine. The subunit EZH2 of the polycomb repressor complex II 
(PRC2) normally mediates the methylation of lysine, but when H3K27 is 
mutated, the methylation is decreased due to less affinity for methionine 
by EZH2. This leads to de-repression of genes, which could be oncogenic. 
H3K27M in HGG is associated with shorter survival time [58].  
 
The other histone mutation, H3G34R/V, also results in global 
hypomethylation. The mutation results in the replacement of guanine by 
arginine or valine, and decreases methylation at the nearby K36 position 
on the histone residue leading to increased transcription of, for example, 
the oncogene MYCN. Moreover, mutations in SETD2 (methyl transferase) 
have been correlated to a decrease in the DNA mismatch repair (MMR) 
system [59, 60]. Mutations in the ATRX gene (involved in telomere 
lengthening) have been identified in one third of the G34R/V group of 
paediatric glioma patients [57, 60].  
 
Unlike genetic mutations, epigenetic alterations are reversible. The 
possibility to reverse tumour-driving properties could be employed for 
developing novel treatment and targeted therapies. Targeting one or many 
epigenetic signature marks in pHGG have been tested during the last years 
as described below.  
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DNMT inhibitors 
The DNMT inhibitor decitabine has previously been described to induce 
differentiation and decrease proliferation of glioma cells [61]. In another 
study, Rajendran et al showed increased levels of all three DNMTs in 
glioma cells. When treated with the DNMT inhibitor 5-azacytidine, the 
expression levels of DNMT1 and 3b levels were decreased and an 
enhanced expression of tumour suppressor genes such as PTEN was shown 
[62]. Yet another study showed that downregulation of DNMT1 leads to 
enhanced chemosensitivity [63]. These results suggest that DNMT 
inhibitors might be used in cancer therapy. No clinical study on DNMT 
inhibitors has been presented in paediatric GBM, but a study on 
medulloblastoma showed promising results with a combination of the 
DNMT1 inhibitor decitabine and the HDAC inhibitor vorinostat [64].   
Histone modification inhibitors 
The histone modifier vorinostat, an FDA approved drug, is the most tested 
HDAC inhibitor for brain tumours. It has been evaluated individually and 
in combination with chemotherapy or radiation on primary and recurrent 
paediatric HGG in several clinical trials [29, 65-67], but no significant 
response has been reported. Another HDAC inhibitor, VPA, has also been 
tested for toxicity and anti-tumour activity in a clinical trial of paediatric 
solid tumours. Two out of the 26 enrolled patients showed response 
(GBM) and minor response (brainstem glioma) to the treatment [68]. Other 
studies on paediatric HGG and GBM have been presented earlier [69, 70].   
 
Another histone modifier is the JMJD3 (H3K27 demethylase) inhibitor 
GSKJ4. Promising results have been reported in vitro, and in in vivo 
studies of xenotransplanted mice where tumour growth reduction was 
shown [71]. Another epigenetic drug targeting the methylation of histone 
tails is a small molecule inhibiting EZH2. In DIPG, H3K27M cells rely on 
PRC2 for proliferation and EZH2 is therefore a potential target in these 
tumours [27].  
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BET inhibitors 
The epigenetic readers, including BET, are also possible targets for 
improving therapy. In adult GBM, the BET inhibitor dBET6 represses the 
proliferation and self-renewal of GBM cells [32]. Treatment with a BET 
inhibitor in combination with an EZH2 inhibitor in mouse DIPG cells 
exhibited better response and inhibited tumour growth both in vivo and in 
vitro when drugs were used in combination rather than individually [72].  
Targeting multiple pathways or modifications in heterogeneous GBM 
tumours will most likely be the key to improve therapeutic response.   
The origin of cancer  
In 1956, Otto Warburg presented his explanation to why cells become 
tumour cells in the article “on the origin of cancer cells” [73]. This 
included metabolic changes in a cell due to fermentation and respiration 
alterations after chemical stress [73]. His theory is highly relevant even 
today [4].  
 
Two different theories on the origin of cancer have been proposed. 1) The 
stochastic model, where progenitors or mature cells in a tumour 
environmental niche gain genetic or epigenetic lesions. This model leads 
to a tumour with multiple sub-clones where the best-fitted tumour cell 
drives the tumour growth [74, 75]. 2) The cancer stem cell (CSC) model, 
where one cell initiates tumour growth and gives rise to further mature 
cells in an hierarchical organisation which resembles that of stem cells 
(Figure 2). Sub-clones can form further down in more differentiated stages 
of tumour cells. The CSC theory have been proposed in for example 
leukaemia [76], brain tumours [77] and breast tumours [78].  
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Figure 2: The cancer stem cell theory. 
Stem cells 
All cells in our body originate from that first cell, in the beginning of 
everything. This cell is a totipotent embryonic stem cell, with the capacity 
for self-renewal, the potential to differentiate into all germ layers 
(mesoderm, endoderm and ectoderm) and the capacity to form necessary 
embryonic tissue and parts of the placenta. The totipotency is lost after a 
few cell divisions, and a pluripotent embryonic stem cell remains. This 
stem cell maintains the capacity of self-renewal and potential to 
differentiate to all germ layers [79].  
 
Pluripotent stem cells are of great interest for organ regeneration and 
transplantation medicine. Reprogramming of somatic cells has been 
performed since John Gurdon entered the stage using nuclear 
reprogramming to make a frog from an egg and a somatic cell in 1960 [80]. 
Over time, reprogramming has evolved through different types of delivery 
methods such as PiggyBac, lenti/adeno virus, episomal transfection, 
Sendai virus, small molecules and mRNA technology. In 2006, Shinya 
Yamanaka first published the protocol for making induced pluripotent 
stem (iPS) cells by adding only four transcription factors; octamer-binding 
transcription factor 4 (OCT4), Kruppel-like factor 4 (KLF4), SRY (sex 
determining region Y)-box 2 (SOX2) and c-myc proto oncogene protein 
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(C-MYC) to mice fibroblasts [81]. This has subsequently been 
successfully performed also using human somatic cells [82]. Exogenous 
expression of pluripotency transcription factors force the cell to start 
transcribing the factors endogenously. This push towards pluripotency 
makes the cell undergo epigenetic changes which drives the cell back to 
an immature state close to that of embryonic stem cells [83].  
 
Adult stems cells are multipotent cells with a lineage-specific 
differentiation path. They are responsible for maintaining homeostasis and 
repairing cells upon injury or cell death, and are rare in the body. Adult 
stem cells are characterised by the capacity to self-generate throughout the 
lifetime of the organ. They should give rise to differentiated cells with a 
mature phenotype that constitute all cell types of the specific tissue. They 
should also integrate into the tissue with appropriate functions of the tissue 
it resides in [84].  
 
The definition of adult stem cells is by many researchers based on only 
two characteristics; morphological appearance and the potential to 
differentiate. One should be aware that adult stem cells are almost 
impossible to distinguish from progenitor cells in the body. Progenitor 
cells are partially differentiated cells that give rise to more differentiated 
cells, but do not possess self-generating ability. To claim the existence of 
adult stem cells, the ability of self-generation throughout life needs to be 
fulfilled [84].  
 
The origin of adult stem cells is unknown. One proposed theory is that 
partially differentiated cells with self-renewal capacity are set aside early 
in the developing process and retained in the organs throughout life [84]. 
Adult stem cells have been identified in the human brain, in the 
subventricular zone (SVZ) and in hippocampus [85, 86]  
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… and cancer stem cells  
Solid tumours are accumulations of cells with uncontrolled proliferation 
and vascular growth. The tumour constitutes cells in different maturation 
stages, presenting various cell surface markers, genetic and/or epigenetic 
changes and growth rates. Moreover they respond to therapy differently 
[87].  
 
Historically, the theory of dormant cells with stemness characteristics that 
give rice to cancer was proposed by the German pathologist Rudolf 
Virchow as early as 1855 [88]. It was not until 1994 the modern theory of 
CSCs was proposed, explaining the role of cancer cells in leukaemia, 
sharing characteristics with normal stem cells [89]. In 2003, CSCs were 
identified in human brain tumours [90] and breast cancer [91].  
 
The American Association of Cancer Research has defined a CSC as a cell 
within a tumour with the capacity of self-renewal and that gives rise to the 
heterogeneous lineages of cancer cells that constitute the tumour [92]. 
When transplanted into mice, human CSCs have been shown to not only 
grow, but also to form multiple cell layer tumours similar to its originating 
tumour [91]. A tumour cell that gains stem cell properties alters pathways 
necessary for stemness, such as the wingless integrated (Wnt)/β-catenin, 
sonic hedgehog (SHH), Notch and telomerase reactivation pathways. 
While altering these pathways, the tumour cell undergoes a transition from 
epithelial cell structure to mesenchymal cell structure known as EMT 
(epithelial to mesenchymal transition). During this transition, epithelial 
polarity is lost, cell morphology changes and E-cadherin is down-regulated 
while N-cadherin is upregulated. EMT can also push the cell into a more 
quiescent state [93].      
 
The term CSC is debated and in the literature, these cells are also called 
cancer-initiating cells, cancer stem-like cells or cancer progenitor cells. It 
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is important to note that CSCs do possess stem cell properties, but are not 
necessarily stem cells. 
Cancer stem cells in HGG 
CSCs in GBM were first reported by Singh in 2004, when he showed that 
not all tumour cells were able to form new tumours in vivo. In this study, 
he demonstrated that the cells that initiated tumours were exclusively cells 
expressing the neural stem cell marker CD133 [90]. Other studies have 
since then, in controversy with Singh, shown that different CSC 
populations exist with both CD133+ and CD133- cells as well as only 
CD133- cells. Tumours driven by CD133- CSCs were found to be less 
malignant [94]. If the coexistence of CD133+ and CD133- CSCs in GBM 
occurs, and should be considered a hallmark of the disease, needs to be 
further investigated [94]. The coexistence of different CSCs in GBM has 
been demonstrated in other studies, strengthening this theory [95, 96]. 
Other surface markers such as integrin α6, CD15/SSEA1 and CD44 have 
also been proposed as CSC-specific in GBM [97, 98]. 
 
A study by Suva et al presented four transcription factors; POU3F2, SOX2, 
SALL2, and OLIG2 that could turn a differentiated GBM cell into a 
tumour-initiating cell. These proteins have also been reported important 
for the maintenance of the CSC state [99].  
 
The maintenance of glioma CSCs depends on many factors, for example 
metabolism, epigenetic/genetic factors, the tumour niche and 
environmental factors. Levels of hypoxia and oxygenation alter the 
metabolism in the cell. When cells are under hypoxia, migration is 
stimulated and cell proliferation is decreased [100]. In addition, EZH2, 
which methylates H3K27 and alters the chromosomal structure of the 
DNA, has also been proposed to be important for maintaining the CSC 
state [101]. 
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The origin of CSCs is not clear. In a study by Jeong Ho Lee et al, the 
authors proposed that the origin of CSCs is adult stem cells migrating from 
the SVZ. In this study, patient material from three different zones in the 
brain in relation to the GBM tissue was collected and profiled. They 
showed that approximately 50% of the 55 patients with GBM had cells in 
the SVZ containing low-level driver mutations for GBM [77].   
Cause of relapse 
When not all cells in the tumour respond to therapy, tumours can relapse 
(Figure 3). The most common treatment following diagnosis is surgery, 
radiation and chemotherapy. Lately, more advanced and sophisticated 
tumour-specific pre-clinical treatments have been introduced using 
epigenetic drugs [61, 64].  
 
Figure 3: CSC resistance to treatment. 
 
Within tumours, cells respond to therapy in different ways. Patients with 
brain tumours that display CD133 have a worse 5-year survival than those 
with CD133 negative tumours [102, 103]. Moreover, stem cell properties 
have been proposed to be the main reason for therapy resistance. CSCs 
possess intrinsic factors that make them less susceptible to treatment than 
more differentiated stages of cells in the tumour. Intrinsic factors that 
contribute to drug resistance are:  
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 stemness induction; alteration of stem cell pathways and EMT 
[93]. 
 drug export; efflux of toxic elements in the cell via ATP-binding 
cassette transporters highly expressed on the cell surface of the 
CSCs [104]. 
 high cell survival; inactivation by, for example mutations, of cell 
cycle regulating genes and apoptotic genes preventing CSCs from 
entering apoptosis [105]. 
 hypoxia; in a hypoxic microenvironment, CSCs activate hypoxia-
inducible factor 1-alpha (HIF1α), which leads to EMT and 
alteration of stemness pathways [106]. 
 quiescence; at a quiescent state, CSCs stop dividing and 
consequently escape treatment that targets fast dividing cells 
[107].  
 
Because of these intrinsic factors, CSCs carry endogenous resistance 
mechanisms against radiotherapy and chemotherapy in a larger extent than 
non-CSCs (tumour bulk cells) [103]. In addition, resistance is also partly 
due to the slower proliferation rate that CSCs possess since current therapy 
targets fast dividing cells [108]. Finding treatment that target CSCs is thus 
important for improving therapeutic efficacy.   
Model systems 
Thomas Henry Huxley, an English biologist specialised in comparative 
anatomy, introduced the principle “We are unlikely to ever know 
everything about every organism. Therefore, we should agree on some 
convenient organism(s) to study in great depth, so that we can use the 
experience of the past (in that organism) to build on in the future. This will 
lead to a body of knowledge in that 'model system' that allows us to design 
appropriate studies of non-model systems to answer important questions 
about their biology” as Kunkel concluded it [109].  
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In the field of medical research, moral and ethical questions should always 
be on the agenda. In “The Principles of Humane Experimental Technique” 
William Russel and Rex Burch coined the three R´s: reduction, 
refinement and replacement [110]. Every researcher should strive to 
fulfil these important words in their research.   
In vitro models 
Human cells can be grown in vitro; maintained in cell culture media and 
stored in an incubator with optimal conditions of CO2, pH and temperature. 
Cells can be cultured in many ways; most commonly as two-dimensional 
(2D), or in three-dimensional (3D) structures. Cells can also be grown in 
co-cultures, e.g. different cell types mixed to create better culture 
conditions.  
 
The first human cell line was derived from a cervical cancer biopsy in 1951 
by George Otto Gey, a biologist at John Hopkins University. The tumour 
cells came from a woman named Henrietta Lacks and were simply named 
HeLa from the first two letters of her first and last name. The HeLa cells 
grow immortally and have been used by thousands of researchers since it 
was established [111]. Today, almost any cell type can be purchased as a 
well-characterised cell line. Cell lines established from patient material, 
that have undergone only a few doublings are called primary cell lines and 
have been shown to be more representative as in vitro models since they 
possess more similarities with the original tumours than non-primary cell 
lines [112, 113].      
Culturing HGG cells 
HGG cell lines and primary cultures have been used in medical research 
to characterise and gain knowledge about specific features and therapeutic 
responses. Many HGG cell lines used today are derived from adult GBM.  
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The benefit of primary adult cell lines as an in vitro model instead of non-
primary cell lines is that the primary cells reflect the patient tumour better, 
which has been shown by several groups [114, 115]. Moreover, focusing 
on only CSCs in the cultures demand serum-free culture conditions since 
serum alters the pheno- and genotype of stem cell cultures [116]. 
 
Bax et al described the phenotypic and molecular differences between 
paediatric and adult GBM highlighting the need for paediatric models 
since many cell lines are established from adult tumours [117]. The first 
primary cell model of paediatric GBM was established during the 1980s. 
Cell cultures from many paediatric brain tumours have since been 
established, mostly for medulloblastoma and ATRT. These cell cultures 
are serum-based and the cells grow as spheres [118]. It was not until 
recently the first serum-free CSC cultures from high-grade paediatric brain 
tumours were presented grown as spheres and adherent cells [119]. 
However, none of the established cell lines was GBM.  
 
All model systems have disadvantages; the lack of environmental stimuli 
in cell cultures is one. Co-cultures could partly overcome this 
disadvantage. In addition, cells do not grow in 2D other than in cultures, 
which makes them sensitive and more vulnerable to exogenous factors. 3D 
cultures could act as a protective state for the cells. Moreover, translating 
drug experiments and concentrations can be hard since tumour cells in 
vitro are fully exposed to the drugs in contrast to tumour cells in the body 
surrounded by tissue. Still, in vitro cultures enable high-throughput 
screening with the potential of discovering new active substances. One 
should however bear in mind that many drugs that have shown great 
potential in vitro have later shown to be ineffective in vivo [120]. This 
again emphasises the need of several models.    
 
In vitro models can be used to gain knowledge and experimental results 
that can be transferred to the next level, in vivo models, with replacement, 
reduction and refinement in mind.  
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In vivo models 
The most common and well-known vertebrates in research are mice, 
xenopus, chicken and zebrafish. A good model organism should be easy to 
handle, inexpensive to maintain, have a short life cycle, be possible to 
genetically modify and have the potential to deliver economically 
important results [121]. �e possibility to study human tumour cells in a 
more natural environment is of great relevance in the translational context 
compared to cells grown in a petri dish.  
Mouse (mus musculus) 
The most common and well-known vertebrate used in brain tumour 
research is immunodeficient mice [122]. Mice fulfil all the criteria for a 
good animal model as mentioned above. Patient-derived xenograft (PDX) 
models of paediatric high-grade brain tumours have been presented. In a 
study by Houghton et al, primary high-grade brain tumour tissue was 
injected subcutaneously in immune-suppressed mice [123]. The 
environmental impact on the tumour cells should ideally be studied in the 
right context, therefore orthotopic models could be beneficial. Patient-
derived orthotopic xenograft (PDOX) injection of primary 
medulloblastoma tissue and DIPG sphere cultures have been shown to 
grow and initiate tumour formation in immune-incompetent mice [124, 
125]. Most recently, Brabets et al presented a PDOX model based on 
injection of multiple entities of paediatric brain tumours, including GBM, 
where tumour tissue and cultured spheres were injected [126]. 
Zebrafish (danio rerio) 
The zebrafish is an animal model with great potential and a feasible option 
in cancer research. It has been used in developmental, disease, toxicology, 
inflammation and cancer-related studies and transgenic animal models 
have been used to study development, inflammation, blood brain barrier 
(BBB) and brain tumours [127-135].  
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Whole genome sequencing of zebrafish has shown similarities with the 
human genome; we are not as different as one might have hoped. 
Approximately 71% of the human genes have an orthologue in zebrafish. 
Of the disease-related genes in human, 82% have at least one orthologue 
in zebrafish [136].  
 
Zebrafish embryos are see-through and maintained in a petri dish making 
them easy to monitor compared to mice foetus. Zebrafish also lack a 
developed immune system in early larval stage thus making them suitable 
for xenotransplantation. In addition, zebrafish enables a high-throughput 
setting compared to mice since they produce many offspring, are easier to 
inject and treat, and require less space.  
Zebrafish models of GBM 
Studying human tumour cells in zebrafish reduces and replaces the 
number of higher vertebrates such as mammals used in a study. It also 
refines the experiment as target mechanisms can be understood or drug 
candidates identified prior to the use of mice. Zebrafish experiments could 
therefore act as a step between cell culture and mice experiments.  
 
Previous zebrafish xenograft glioma models have been established by 
injecting rat glioma and human glioma U87 cells into the yolk-sac (the 
source of nutrition for the embryo) of the embryo, studying the migration 
of tumour cells [137-139]. However, the importance of studying cells in 
their natural microenvironment, the brain, was emphasised by Lal et al. 
They showed that glioma cells injected into the yolk of the embryo resulted 
in an absence of invasion into the surrounding tissue, questioning the 
relevance of that model [140]. Orthotopic models have therefore been 
developed to meet the demands of biological relevance. In a study by 
Welker et al, adult primary human GBM spheres survived when 
orthotopically transplanted into the fish brain and later responded to 
treatment [141].  
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Eden et al presented a different approach using adult zebrafish 
orthotopically transplanted with murine GBM cells [142]. This approach 
could be more useful for studying adult GBM, since the host mimic the 
adult setting better. In this study, the fish needed to be immunosuppressed 
since the adult fish is immune competent.  
 
In a recent study, a new model was presented [143]. Human adult GBM 
cell lines and primary GBM cells were injected into the blastula of the 
embryos. The glioma cells subsequently migrated to the brain of the 24h 
old embryo. This model provides a quicker experimental procedure since 
the larvae does not have to be anesthetized or embedded prior to injection.  
How suitable are zebrafish for testing human drugs?  
Zebrafish as an animal model in drug research offers technical and 
biological advantages. However, are fish suitable for testing human drugs? 
Do they provide clinical relevance? Humans and zebrafish are 
phylogenetically further apart than humans and mice and it is important to 
understand these differences when evaluating the capabilities and 
limitations of this model. As mentioned, zebrafish harbour an orthologue 
counterpart to more than 80% of human disease-related genes. Ten of the 
most prescribed human drugs have target genes with sequences that match 
with more than 50%. This might not strike as similar, but the active binding 
site of the protein is in the most conserved parts of the gene sequence, 
which makes it functionally more similar than at a first glance [144].  
 
The physiology of organs in fish matches the human and carry out the same 
functions. For example, the zebrafish pancreas comprises all the same cell 
types as the human pancreas and drugs that alter the glucose homeostasis 
show the same effect in fish as in humans [145]. Likewise, the 
haematopoietic system is built up by the same cell types [146] showing 
conserved haematopoietic pathways. This results in a similar cellular 
response to drugs affecting haematopoiesis and anaemia in humans and 
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zebrafish [147]. Interestingly, key factors in these pathways and processes 
were first discovered in zebrafish [148]. Many cardiovascular drugs have 
been tested in zebrafish with similar response as in humans [149]. Even 
more interesting is that zebrafish share more similarities with the human 
cardiac electrophysiology than rodents do to humans. 
 
Not only do small molecules affect cells in the same way in zebrafish as 
they do in humans, there is also evidence for drugs passing through 
biological boundaries as the BBB and tissue-specific transporters in the 
same way in zebrafish as in humans [150, 151]. In an orthotopic xenograft 
study of GBM in zebrafish by Zeng et al, a nitrogen mustard-based DNA 
cross-linking small chemical, TN-B, was evaluated as a treatment 
candidate [152]. To test if the molecule could cross the BBB, TN-B was 
injected simultaneously with doxorubicin (known for not passing the 
BBB), resulting in doxorubicin remaining in the capillaries of the brain 
while TN-B crossed and diffused out into the brain. Treatment with TN-B 
resulted in a decrease of the xenograft tumour [152].    
 
To summarise, the zebrafish offers a suitable and complementary animal 
model to the mouse models commonly used today. Zebrafish bridges the 
gap between in vitro and higher in vivo models while taking reduction, 
refinement and replacement into account.   
 
The use of in vitro and in vivo models in pre-clinical studies paves the way 
to reach novel treatment options (Figure 4). The molecular insight into 
treatment response in several models increases the knowledge for further 
testing.   
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Figure 4: A schematic view on how different models can be used in drug 
discovery. 
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Objectives  
The overall aim of this thesis was to create representative, stable and well-
characterised cell-based models of paediatric HGG. These models allow 
for the identification of better treatment options as well as an increased 
understanding of biological and mechanistic processes in tumours.  
Specific aims 
Paper I 
• Establish a robust, well-characterised, in vitro system for primary 
HGG stem cells  
• Explore the possibilities of using the system for identification of 
improved therapy 
 
Paper II 
• Establish an orthotopic primary human HGG xenograft mouse 
model 
• Study the clinical relevance of the model 
 
Paper III 
• Establish an orthotopic primary human HGG xenograft zebrafish 
model 
• Evaluate the use of the model to identify therapeutic candidates 
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Methodology 
In this thesis, the same patient material was used in the studies; paper I (in 
vitro), paper II (in vivo) and paper III (in vivo).  
Patient material 
Regional ethical approval was obtained for the studies (Dnr 604-12). 
Patient material was donated from children operated for a high-grade brain 
tumour and signed informed consent was obtained from the parents. Tissue 
was collected during surgery and was taken to the cell lab for culture 
preparation within an hour.   
Cell culture 
In paper I, tumour tissue was mechanically and enzymatically dissociated 
prior to seeding in culture dishes. Cells were cultured in a serum-free stem 
cell media containing DMEM-F12 and supplemented with B27, N2 and 
the growth factor EGF. In this thesis, seven primary paediatric HGG stem 
cell cultures were established and used; GU-pBT-7 (called BPC-A7 in 
paper I), GU-pBT-10 (BPC-B0), GU-pBT-15 (BPC-B5), GU-pBT-19 
(BPC-B9), GU-pBT-23 (BPC-C3), GU-pBT-28 (BPC-C8) and GU-pBT-
58. 
 
Cells were cultured adherently in culture dishes coated with laminin to 
facilitate cell attachment, or as sphere cultures in low attachment 96-well 
plates without laminin. Adherent cells were kept in cell culture for up to 
30 passages. 
 
To enrich for stem cells and maintain proliferating and non-differentiated 
cell cultures, EGF was added to the media and the cells were cultured 
adherently on laminin. A previous study showed that laminin helps 
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preserve stem cell features in the presence of EGF and in the absence of 
fibroblast growth factor (FGF) [153]. The study showed that culturing cells 
on gelatin with removal of both growth factors resulted in astrocyte 
differentiation and failure of cell culture establishment. Even with the 
addition of EGF, cells stopped proliferating and died. However, 
replacement of gelatin with laminin, in the presence of only EGF, resulted 
in viable and proliferating cells. This study concluded that EGF allows for 
neural stem cell cultures and self-renewal of these cells. Other studies by 
Pollard et al and Sun et al also showed the requirement of EGF in neural 
stem cell culturing [154, 155].  
Immunocytochemistry and immunohistochemistry 
When visualising proteins or antigens in cells or tissues, immunocyto- and 
immunohistochemistry are commonly used. These two methods are based 
on the same antigen-antibody interaction technique. The method was first 
introduced in the 1940s by Albert H Coons, who studied the possibility to 
detect antibodies by using optical tracing [156].  
 
Simplified, the refined methods are based on a primary antibody binding 
to the antigen of interest, which is then detected by a secondary antibody 
with a detection probe. Commonly used detection probes are horseradish 
peroxidase (HRP) or fluorochromes. HRP catalyses the cleavage of the 
chromogen DAB (3,3′-Diaminobenzidine) which in turn is visualised 
under a light microscope. The HRP can be used as a detection probe in 
numerous ways. A fluorochrome does not need any additional reactions 
and can be directly visualised under a fluorescent microscope.  
 
It is important to evaluate the specificity of the antigen-antibody 
interaction as antibodies can bind un-specifically, thus creating 
background, or bind to closely related antigens. In addition, 
immunohistochemistry requires blocking of the endogenous HRP that is 
present in tissues.  
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In paper I, stem cell specific antibodies against NESTIN, SOX2, OLIG2 
and VIMENTIN were detected by a fluorescent conjugated secondary 
antibody. Moreover, differentiation of the CSCs was demonstrated using 
antibodies against the neuronal marker MAP2 and the astrocyte marker 
Glial fibrillary acidic protein (GFAP). To measure proliferation rate, 5-
ethynyl-2-deoxyuridine (EdU) was added to the cell culture, to be 
incorporated into the genome upon mitosis, 24 hours prior to fixation and 
detected with a direct fluorescent primary antibody.  
 
In paper I, II and III, immunohistochemistry was performed by staining for 
human NESTIN, to demonstrate the presence of human GSCs in the mice 
and fish brains. In these studies, a HRP conjugated secondary antibody was 
used and the intensity was amplified with an avidin-biotin complex. In 
addition, the mice brains were stained with the proliferation marker Ki-67 
using the same secondary antibody complex. 
PDOX mouse model 
Prior to transplantation, adherent cells in the exponential phase were 
enzymatically detached, counted and re-suspended in PBS, and kept on ice 
until transplantation.   
 
Immunocompromised NOG mice, 6-8 weeks old females, were used for 
the mouse xenograft model in paper I and II. The mice were anesthetised 
and placed in a stereotactic frame. The top of the head was shaved and the 
scull was visualised using a scalpel. To pass through the scull, a hole was 
drilled approximately 1mm rostral and 2mm lateral (right) to bregma using 
a hand drill. 100 000 cells in 1µl were injected at a depth of 2.5 mm into 
the putamen on the right side of the brain [157]. 
 
Mice were monitored and weighed continuously until they reached the 
endpoint when they were euthanized due to weight-loss or physical 
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disabilities. Brains were removed and fixed in 4% PFA before paraffin-
embedding and stored at room temperature until sectioning using a 
microtome when 5µm sections were mounted on super-frost glass. 
 
In paper I, three GSC lines were used in the PDOX model. In paper II, 
these three PDOX models were further evaluated together with three new 
PDOX models. 
DNA methylation analysis 
For the methylation studies in paper I and II, DNA from tumours and CSC 
cultures and xenograft mouse tumours, was isolated. To detect methylated 
cytosines in the samples, bisulfite modification was used, which converts 
all unmethylated cytosines to uracils (U) [158]. The modified DNA was 
then amplified by PCR, where the U is amplified as a T.  
 
Methylation values of 450 000 or 850 000 CpG sites, distributed over 
gene-populated areas of the genome, was measured with the Infinium 
HumanMethylation450 BeadChip and Infinium MethylationEPIC 
BeadChip. The array is constructed by a two-coloured system emitting 
different colours depending on the methylation status of the original DNA 
strand. The methylation data was analysed using the programming 
software R (http://www.R-project.org/) with the R-package ChAMP [159]. 
The relationship between methylated and unmethylated sites is calculated 
as: 
𝛽𝛽 = max (𝑦𝑦𝑚𝑚𝑚𝑚𝑚𝑚ℎ, 0)max(𝑦𝑦𝑢𝑢𝑢𝑢−𝑚𝑚𝑚𝑚𝑚𝑚ℎ, 0) + max(𝑦𝑦𝑚𝑚𝑚𝑚𝑚𝑚ℎ, 0) + α 
 
where ymeth and yun-meth are emission intensities and α is set to 100 [160]. 
The β value ranges between 0 and 1 where β = 0 is completely 
unmethylated and β = 1 is completely methylated. Clustering analysis and 
identification of differentially methylated positions (DMP) were 
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performed using the methylation values. CNA were inferred from the 
methylation data using the conumee R package [161]. 
PDOX zebrafish model 
Prior to transplantation, adherent cells were evaluated as in paper II. Cells 
were labelled with CellBrite Cytoplasmic Membrane Dye, a fluorescent 
membrane dye that enables detection of cells.  
 
In paper III, zebrafish AB wild-type eggs were collected at 0 days post 
fertilisation (dpf) and sorted based on quality. Embryos were maintained 
in embryo media (EM) and kept at 28.5°C. At 24 hours post fertilisation, 
eggs were placed in EM containing 0.003 % w/v 1-phenyl 2-thiourea 
(PTU) and kept in PTU throughout the experiment to prevent 
pigmentation.  
 
Xenograft transplantation was performed at 2 dpf and unhatched larvae 
were dechorionised using forceps. Larvae were anesthetised and 
embedded in low-melting agarose to maintain a fixed position during the 
procedure. Cells were loaded into a glass capillary, which was attached to 
a Narishige MN-153 micromanipulator, and connected to an air-driven 
Picospritzer microinjector. Approximately 100 cells in a volume of 1 nl 
were injected by inserting the needle into the forebrain ventricles. Larvae 
were removed from the agarose after the injection, placed in ringer solution 
containing PTU and kept in well-plates at 34.5°C. 
 
Larvae were monitored using confocal imaging at 1 day post injection 
(dpi), 5 dpi and 8-9 dpi. Larvae were also fresh frozen in optimal cutting 
temperature (OCT) compound at 1 dpi and 8-9 dpi for 
immunohistochemistry and stored at -80°C until sectioning. Brains were 
sectioned using a cryostat and 8µm sections were mounted on super-frost 
glass. 
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Live imaging 
A LSA 710 confocal microscope (Zeiss) was used to monitor glioma cells 
in the larvae brain in paper III. Larvae were anesthetised and embedded in 
low-melting agarose to keep the animal fixed during imaging. Fluorescent 
cells were visualised at 644 nm and a Z stack of 2µm of the larvae brain 
was acquired by the ZEN Zeiss software. The difference in area of tumour 
cells in the ventricle area was measured at 1 dpi and 5 dpi and the distance 
that cells had invaded into the brain was measured at 5 dpi using Image J 
(NIH) [162, 163].  
Statistical methods 
Pearson product moment correlation (Pearson correlation) 
The strength of a linear association between two variables (x and y) can be 
measured by Pearson correlation (r) as illustrated below. The values of r 
range from -1 to 1, where r < 0 is a negative correlation and r > 0 a positive 
correlation and 0 means no correlation. The closer r is to -1 and 1, the 
stronger the correlation is.  
𝑟𝑟 = ∑𝑥𝑥𝑦𝑦
�∑𝑥𝑥2 ∑𝑦𝑦2
 
Kaplan-Meier survival analysis 
In paper I and II, the Kaplan-Meier survival analysis was used to describe 
the percentage of animals alive after a certain time during the experiment 
[164].   
Bliss independence model 
In paper III, the effect of two independent drugs added in combination was 
evaluated in an attempt to increase the treatment effect. Even though the 
combination of two drugs results in an increased effect compared to the 
single drugs alone, we have no knowledge about the relation between the 
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drugs. Drugs can act in synergy or non-synergy, which is explained in the 
Bliss independence model [165]. The interaction score is calculated by 
subtracting the expected effect from the observed effect. The observed 
effect (DAB) is the result shown in the experiment while the expected effect 
(DADB) is the product of the observed effect from the single drugs.     
Interaction score (ℇ) is calculated: 
ℇ = DAB - DADB 
ℇ < 0 synergy 
ℇ > 0 non-synergy 
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Results and discussion 
Paper I: Stem cell cultures derived from pediatric 
brain tumors accurately model the originating 
tumors 
HGG is molecularly not the same in adults and children, and available GSC 
cultures have been established from adults only. In this study, we therefore 
assessed the possibility to culture primary high-grade GSCs, from 
children, in vitro. An illustration is presented in Figure 5. 
 
 
Figure 5: Illustration of the GSC culture in vitro model. Proliferating cells are 
visualised in green (left). Neural stem cells markers; NESTIN (orange) and SOX2 
(green). Differentiation capacity; demonstrated with expression of the astrocytic 
marker GFAP (orange) and the neuronal marker MAP2 (green). 
 
Six primary GSC lines were established. The cells were cultured 
adherently in serum-free neural stem cell media and was maintained for 30 
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passages. Genomic and epigenomic analyses of the primary cell cultures 
showed that the cells were stable during culturing and thus represented a 
robust model. The cells were positive for stem cell markers and responded 
to differentiation cues. Three out of three tested primary cell lines initiated 
tumour growth when orthotopically transplanted into mice.  
 
Tumour samples from the six patients in this study, were diagnosed 
histologically and by DNA methylation-based classification using the 
MethPed algorithm [22]. Tumours were diagnosed as GBM, PNET and 
ATRT by histological diagnosis. In contrast, MethPed classified all 
samples as GBM. Additional molecular analyses and a second histological 
review performed by a senior pathologist confirmed the GBM diagnose for 
all samples.  
 
The tumour cells proliferated at a steady rate during the 30 passages they 
were kept in culture (rate dependent on cell line), and they were positive 
for the neural stem cell markers NESTIN, SOX2, OLIG2 and VIMENTIN. 
When treated with differentiation agents, cells responded by a decrease in 
proliferation, loss of neural stem cell markers and increase in astrocyte and 
neuronal cell markers.  
 
To evaluate the tumour-initiating capacity, three of the primary cell lines 
were orthotopically injected into NOG mice, with a tumour take-rate close 
to 100% (14/15 injected mice developed tumours). To further prove 
tumour-initiating capacity of the GSCs, one primary cell line was also 
orthotopically injected into zebrafish larvae, showing invasive tumour 
growth after only a few days. To emphasise the importance of using 
primary cell lines and the fact that non-primary cell lines lose their tumour 
characteristics, the adult GBM cell line U87 was injected into the zebrafish 
larval brain. U87 did not show the characteristic invasive growth pattern 
of GBM, highlighting the lack of relevance of such a cell line (Figure 6). 
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Thus, the relevance of the cells used in studies should be considered to 
enable accurate conclusions to be drawn.   
 
 
Figure 6: The invasive growth pattern of the primary cell line GU-pBT-7 
compared to the non-primary GBM cell line U87 (both labeled with RFP) in larval 
zebrafish. 
Genetic aberrations in tumours are common, although paediatric GBM 
generally have less genomic instability than adult GBM. CNA inferred 
from methylation data [166] from tumour tissue in our study showed 
common aberrations such as EGFR amplification and deletions in RB1, 
cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and phosphatase and 
tensin homolog (PTEN). CNA analysis of the tumours and the 
corresponding GSC lines showed similar profiles. 
 
To evaluate the stability of the DNA methylation in this in vitro model, the 
methylation pattern of the originating tumour and GSCs from the primary 
cell cultures were compared. In hierarchical cluster analysis, the GSCs 
grouped together with its originating tumour and separate from the other 
cell lines. Further, examining the DMP identified that less than 4% of the 
studied CpG sites changed methylation state, strengthening the relevance 
of this in vitro model for DNA methylation studies.   
 
Cell lines can alter molecular and physical properties after serial passages 
in culture due to selection of cells. Sub-clones, or tumour-specific 
aberrations, can be lost, thereby making the cell line irrelevant for the 
purpose. Continuous evaluations of cell lines should therefore be 
performed to ensure that specific tumour characteristics are not lost over 
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time. In this study, samples were therefore taken from different passages 
to evaluate the molecular stability and robustness of the cell culture, which 
showed a close relationship between low, middle and high passage cells.  
 
The use of primary cell cultures instead of non-primary cell lines in cancer 
research have many advantages. Cell lines that have been cultured for 
several years might not resemble the original sample. A few years ago, it 
was shown that the commonly used adult GBM line, U87, did not show 
similarities with the originating tissue sample and early-cultured cells 
[167]. This highlights the need for thorough validations of cell lines that 
are used as basic material in many research projects. The use of primary 
cell lines reflects tumour properties and specific characteristics of the 
tumours and add the clinical relevance enabling personalised treatment 
designs. For example, drug screening in a xenograft zebrafish model with 
a fast disease course could guide patient treatment. 
 
Moreover, depending on the aim of the study, the experimental set up 
should promote correct culture conditions. Many GBM tumours exhibit 
EGFR amplification, but this is lost when culturing cells in media 
supplemented with EGF [168]. For experiments when it is important that 
the EGFR amplification is retained, optimised culture conditions should be 
used. In this study, we showed that cells cultured without EGF but with the 
supplement of another growth factor (FGF), retained the EGFR 
amplification after several passages.  
 
The tumour-initiating capacity of CSCs is a fundamental characteristic 
where tumour formation is a proof of stem cell capacity. The growth 
pattern and specific morphology of the xenograft tumours are of utmost 
importance to show clinical relevance. In previous studies, primary CSC 
lines from paediatric high-grade brain tumours have been described [119]. 
Tumour-initiating capacity from one of the cell lines, a medulloblastoma 
group 3, proved the CSC characteristics of that culture in a later publication 
[169]. 
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An advantage of culturing cells adherently in 2D cultures is that it 
facilitates the analysis of morphological changes. In addition, cell 
proliferation and presence of specific antigens can easily be evaluated. The 
limitations of a 2D cell culture is obviously the lack of the 3D environment 
that cells are part of in the body. The cell-to-cell communication in a 
heterogeneous tumour in the body could be mimicked by co-culturing cells 
either in 2D or 3D to better resemble the natural habitat. Further, culture 
models that mimic the natural habitat even closer have recently been 
published by Marques-Torrejon et al who cultured GSCs in sections of 
mouse brain tissue [170]. This study showed that sections of mouse brain 
could survive in serum-free media for weeks. GSCs can be injected in 
specific areas studying growth pattern and environmental influences in 
different parts of the brain. The model is an interesting addition with great 
potential as a co-culture system between the in vitro and in vivo setting.  
 
In this study, we presented a robust and representative adherent serum-free 
cell culture model established from six paediatric primary high-grade brain 
tumours. The model is well-characterised showing CSC properties and 
display genomic and epigenomic stability, with profiles resembling the 
originating tumours.  
Paper II: Cell line-based xenograft mouse model of 
paediatric glioma stem cells mirrors the clinical 
course of the patient 
Prior to this study, no cell line-based paediatric glioma xenograft model 
had been described. In paper II, tumour-initiating capacity of primary GSC 
lines were assessed and a paediatric GSC-based PDOX model in mice was 
established. Six primary GSC lines were transplanted into NOG mice and 
the survival time of the mice was studied. The morphology and growth 
pattern of the tumour cells in the xenograft tumours was assessed. The 
diagnosis of the xenograft tumours were based on histological diagnosis 
and molecular diagnosis. Further, genetic and epigenetic stability of the 
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xenograft tumours in comparison to the GSC lines and the originating 
tumours were evaluated. The model is illustrated in Figure 7.  
 
 
Figure 7: Illustration of the orthotopic HGG mouse xenograft model.  
 
In this study, six GSC lines were orthotopically transplanted into 
immunosuppressed mice. Take-rate for each GSC line was close to 100% 
(29/30 mice) and the time-span between deaths were close in each group.  
 
The survival time of mice correlated well with the patient survival time. 
This is of utmost importance since the GSCs produce a tumour with similar 
features in the context of growth patterns as the originating patient tumour. 
A robust and reliable in vivo model is important to draw relevant 
conclusions from experiments.  
 
All xenograft tumours presented GBM characteristics of diffuse 
infiltration, endothelial proliferation and atypical mitosis. Moreover, 
xenograft GBM tumours formed Scherer´s secondary structures with 
perineuronal and leptomeningeal accumulation and perivascular 
infiltration. The proliferation marker Ki-67 indicated massive tumour 
growth. Additionally, all xenograft tumours were diagnosed as GBM using 
the MethPed classifier [22].   
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Further characterisation of the xenograft tumours showed that genetic 
aberrations seen in the tumour tissue and GSC lines, were also present in 
the xenograft tumours. The epigenetic stability was visualised in a 
hierarchical clustering, which clustered the originating tumour, GSC line 
and xenograft tumour together based on DNA methylation data.  
 
Establishing xenograft mouse models can be done in different ways. Other 
PDOX models were based on transplantation of human paediatric tumour 
tissue into mice [126, 171]. This approach is time consuming and 
expensive since cell lines have to be established by serial passaging in mice 
prior to experimental testing. According to the engraftment rates in the 
Children’s Oncology Group biobank, the success of HGG tumour 
formation was approximately 30% [126]. In another study by Kim et al, it 
was shown that transplantation of glioma tissue failed to engraft [172]. 
Depending on how many tumour-initiating cells that are transplanted into 
each mouse, the tumour growth and survival of the mice will differ. In 
contrast, cell line-based xenograft models produce a uniform model where 
all tumours are formed from GSCs. This is an advantage when comparing 
results from different xenograft experiments and it reduces the number of 
animals needed. This is in stark contrast to the uncertainty of engraftment 
using tumour tissue, which contributes to unnecessary use of animals. 
Moreover, Ben-David et al showed that human cells could be influenced 
by the mouse environment after serial passaging, thus altering important 
features of human tumour cells [173]. By using cell lines established in 
vitro, the serial passaging of human tumour cells in mice can be avoided.     
 
As with all animal models, there are limitations. The obvious one is that a 
mouse is not a human. Although the mouse brain contains all the same cell 
types as in humans, the mouse is still a mouse. The impact of mouse cells 
on human cells will alter the human GBM cells over time in any model. 
Moreover, the xenotransplanted mice are immunosuppressed to allow for 
an allogenic tumour growth, which is a disadvantage. Further, the 
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experimental time from initiation of a tumour to the completion of the 
experiments is long and it can take many months to get results from a 
study.    
 
Even with limitations, our model offers a robust and reliable alternative to 
previous mouse models, and is to our knowledge the first paediatric 
primary cell-based model that correlates with patient survival, which 
strengthens the clinical relevance of the model.  
 
An advantage of cell-based models is that fewer mice are used, since 
passaging and establishment of primary cell lines are performed in cell 
culture. With fewer animals used, this model offers a less expensive and 
less work-demanding model. The model is therefore in agreement with 
both reduction and replacement.  
Paper III: Invasion of human paediatric high-grade 
gliomas in zebrafish 
In paper III, we explored the use of zebrafish as an additional animal model 
for paediatric HGG. The previous pilot study in paper I showed promising 
results that were elaborated in this study. Tumour invasive properties of 
five GSC lines were studied. As a proof of concept, treatment response to 
TMZ, VPA and decitabine was evaluated (Figure 8).  
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Figure 8: Illustration of the zebrafish model. GSCs are stained red prior to 
injection using a membrane dye.    
Zebrafish have been used as transgenic models, PDX and PDOX models 
in different types of disease-related research [129, 130, 137, 141, 149]. 
This animal model offers a feasible, fast, less expensive and 
experimentally less work-demanding model compared to other commonly 
used models such as rodents.  
 
In this study, five primary paediatric GSC lines were orthotopically 
injected into the frontal ventricles of the zebrafish larvae. This resulted in 
tumour cell invasion in 98% of the cases. Post-injected deaths due to 
technical injuries were low; only 4/60 animals had to be removed from the 
study. Compared to a previous model where injections were performed 
into the blastula of the egg, transplanting tumour cells into the larvae, as 
done in this study, generated a higher take-rate which allows less animals 
to be used [143]. Invasion was assessed at 5 dpi by counting the number 
of tumour cells in the brain tissue and the distance the cells had migrated 
from the midline of the brain.  
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As mentioned in paper II, GBM is characterised by diffuse infiltration. 
Compared to the infiltrative pattern of the GBM cell line U87 in paper I, 
where infiltration was completely absent, this primary cell line-based 
model showed infiltrative properties.  
 
One technical difficulty with using zebrafish as an animal model is the 
difference in temperature that fish and human cells require. The natural 
laboratory habitat for zebrafish is a water temperature of 28°C while the 
human cells grow at 37°C. To adjust for the temperature difference, 
previous studies have been carried out housing the fish at 34°C post 
injection since zebrafish have been shown to survive a habitat of higher 
temperatures without developing malformations and disabilities [137, 141, 
142]. In addition, in our study, the primary GSC lines continued to 
proliferate and were viable, in vitro, at 34°C, although the proliferation 
was slower. There is no consensus in the literature regarding which 
temperature the human tumour cells should be cultured at prior to injection 
[141, 142]. We therefore compared the two culture conditions (34 and 
37°C) prior to injection to study the take-rate and invasive properties. This 
resulted in no difference between the two temperatures. We thus concluded 
that human tumour cells do not have to be acclimatised to the lower 
temperature and can therefore be grown at 37°C prior to injection without 
affecting the result.  
 
GSCs were visualised in the fish brain with an antibody specific for human 
NESTIN, a neural stem cell marker. GSCs were present the day after 
injection and after 8-9 days, demonstrating that human cells survive in the 
fish brain.   
 
To evaluate the use of the developed models for drug testing, three primary 
GSC lines were treated, in vitro, with TMZ, VPA and decitabine, which 
resulted in a significant decrease (p-value < 0.05) in number of cells for all 
treatments. In addition, the combination of TMZ and VPA resulted in an 
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enhanced treatment response due to a synergy effect between the drugs, 
calculated with the Bliss-independence model.  
 
The drug treatments were also performed in vivo using larvae injected with 
the GSC culture GU-pBT-19. Drugs were added to the EM in a 
concentration that allowed for normal development of the larvae. 
Treatment response was evaluated at 5 dpi and resulted in a decreased 
number of tumour cells that had invaded the fish brain. This correlated 
strongly with the results from the in vitro study.   
 
The use of primary GSC lines makes it possible to study patient-specific 
treatment alternatives and propose further treatment within a feasible time 
to benefit the patient. In paper I, and in previous studies by others, it was 
shown that the survival time of tumour-injected larvae was approximately 
10-30 days [141, 142]. This is an advantage studying personalised 
treatment strategies as results can be obtained in a timely manner. 
However, treatment that spans over a longer period could be harder to 
achieve using this model.  
 
A disadvantage of fish in comparison to mammalian models include the 
absence of specific organs such as breast, prostate and lungs. Orthotopical 
xenograft models are consequently not an option for studies in these 
organs. In addition, studies of immune response in early life are not 
possible due to the lack of an adaptive immune system.  
 
To summarise, in this study we show that zebrafish is a feasible animal 
model for primary paediatric HGG. The model enables cell invasion 
studies and evaluation of treatment potential. This model shows stable 
tumour initiation and high transplantation take-rate using multiple cell 
lines.  
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Conclusion and future perspective 
This thesis contributes to cancer research by presenting three pre-clinical 
models of paediatric HGG. Pre-clinical work is of importance for finding 
better treatment solutions, avoiding toxic drug effects and evaluating 
patient-based strategies. Pre-clinical models contribute with results and 
conclusions that are passed on to the next model with the hopes of reaching 
human studies and benefit patients. Creating a perfect model is not possible 
though, as animals are different from humans, but this should not 
discourage us. The use of primary tumour tissue and primary cell lines 
provides the possibility to create models reflecting the patient diversity. 
This is a great advantage over the use of traditional cell lines, as in fact, 
humans are different from humans too.  
 
To conclude, the in vitro model presents serum-free cell lines 
representative of the originating tumours. The workload is less demanding 
than using a PDX model to establish a cell line. In contrast to using 
traditional cell lines, primary cell lines add patient specificity that gives a 
broader knowledge contributing to the clinical relevance.  
 
The in vivo mouse PDOX model introduces the missing piece, the 
paediatric angle, important and needed. Children are not tiny adults, and 
should therefore have pre-clinical models based on the right type of 
material. In this study, the clinical relevance is highlighted in the 
similarities between the original tumour and the xenograft tumour. The 
correlation in survival time between patients and mice shows that the 
model mimic the clinical course of the patient.  
 
The zebrafish PDOX model contributes to the research field by adding a 
novel and interesting approach to the in vivo stage. Although previous 
models have shown that human brain tumours can grow in fish, we show 
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that primary cell lines based on paediatric tumours can be used in this 
model.  
 
Both in vivo models presented in this thesis are based on immune 
incompetent animals. One of the hallmarks of cancer points out the close 
interaction between cancer cells and immune cells. For this reason, novel 
models using immunocompetent animals in xenograft studies are under 
development and should be considered in paediatric studies [174].  
  
Pre-clinical models are of great interest and a necessity in medical 
research. Different research questions require different applications and 
models. Every new model can increase our knowledge, which enable us to 
develop new models that are more precise. Remember; reduction, 
refinement and replacement.  
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